NanoViricides (NYSE-A:NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 in development for MPox and Smallpox was shown to be “highly effective” for these indications in an animal model.
During the trial, animals treated with NV-387 matched the 14-day survival rate of animals on oral Tecovirimat, an approved smallpox therapeutic.
Untreated and vehicle-treated animals died in eight days, indicating a 75% increase in lifespan for animals treated with NV-387 and Tecovirimat.
"We believe that non-dilutive government funding may be possible for the development of an NV-387-based drug for the treatment of Smallpox and Mpox, given these excellent results," Dr. Anil Diwan, NanoViricides (NYSE-A:NNVC) president, said in a statement.
Additionally, NV-387 is currently in Phase 1a/1b human clinical trials for the COVID-19 indication in India in two oral formulations.
So far, the study has shown that the drug displays broad-spectrum activity against COVID and has also indicated that it is active in viruses in the genus of Orthopoxviruses as well.
With 26 out of 36 patients having completed the trial, there have been no reports of adverse events or serious adverse events, indicating these formulations are safe in humans, the company said.
NanoViricides (NYSE-A:NNVC) is a development stage company that is creating special-purpose nanomaterials for antiviral therapy.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie